Videos

Marisa Papaluca on Personalised Medicine Regulatory Issues

Language
English
Duration
12.00 minutes

Interview with Marisa Papaluca, Senior Scientific Advisor, European Medicines Agency (EMA)

At ECRIN's International Clinical Trials Day (ICTD) 2016 meeting in Prague, Czech Republic, Marisa Papaluca responded to the following:

  • What are the main regulatory pathways and challenges for personalised medicine in Europe?
  • Can you provide a specific example of a regulatory issue and how it was resolved?

Ian Roberts on Methodological Considerations for Personalised Medicine

Language
English
Duration
6.00 minutes

Interview with Ian Roberts, Professor of Epidemiology and Public Health, London School of Hygiene & Tropical Medicine (LSHTM)

At ECRIN's International Clinical Trials Day (ICTD) 2016 meeting in Prague, Czech Republic, Ian Roberts responded to the following:

  • What are the key methodological considerations of clinical trials on personalised medicine?
  • What are the main changes in methodological standards and expected impact?

Denis Horgan on Personalised Medicine Perspectives & Access

Language
English
Duration
4.00 minutes

Interview with Denis Horgan, Executive Director, European Alliance for Personalised Medicine

At ECRIN's International Clinical Trials Day (ICTD) 2016 meeting in Prague, Czech Republic, Denis Horgan responded to the following:

  • What are the main perspectives to consider when it comes to personalised medicine?
  • How can we make access to personalised medicine a reality for patients and ensure that the right treatment is provided to the right patient at the right time?

Dhavendra Kumar on Personalised & Evidence-Based Medicine

Language
English
Duration
15.00 minutes

Interview with Dhavendra Kumar, Consultant in Clinical Genetics, Institute of Cancer & Genetics, Cardiff University School of Medicine

At ECRIN's International Clinical Trials Day (ICTD) 2016 meeting in Prague, Czech Republic, Dhavendra Kumar responded to the following:

  • What is the definition of personalised medicine and evidence-based medicine, and what do they mean in relation to clinical trials?
  • What is the potential impact of evidence-based medicine on public health?

Jacques Demotes, ECRIN's Director General, Presents ECRIN

Language
English
Duration
6.00 minutes

Shortcuts: 

  • What is ECRIN about? (0:05)
  • How is ECRIN organised? (0:32)
  • What are ECRIN's major achievements? (1:25)
  • What is the future of ECRIN? (2:04)
  • What are the benefits for countries to join ECRIN? (2:51)
  • Will ECRIN lead to a brighter future for multinational clinical research? (3:33)
  • How does ECRIN benefit patients? (4:26)
  • Does ECRIN collaborate with industry? (4:57)
  • Will ECRIN only focus on drug trials? (5:31)